Warren Dewayne Heston
#167,518
Most Influential Person Now
Warren Dewayne Heston's AcademicInfluence.com Rankings
Warren Dewayne Hestonphilosophy Degrees
Philosophy
#9933
World Rank
#13565
Historical Rank
Logic
#6884
World Rank
#8442
Historical Rank
Warren Dewayne Hestonbiology Degrees
Biology
#13657
World Rank
#17212
Historical Rank
Molecular Biology
#2330
World Rank
#2365
Historical Rank
Biochemistry
#2408
World Rank
#2559
Historical Rank
Download Badge
Philosophy Biology
Why Is Warren Dewayne Heston Influential?
(Suggest an Edit or Addition)Warren Dewayne Heston's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Prostate-specific membrane antigen expression in normal and malignant human tissues. (1997) (1334)
- Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. (1999) (763)
- Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer (2004) (701)
- Expression of the prostate-specific membrane antigen. (1994) (573)
- Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. (1993) (524)
- Prostate-specific membrane antigen is produced in tumor-associated neovasculature. (1999) (418)
- Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. (1996) (361)
- Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. (1995) (263)
- Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer (2005) (242)
- Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. (1999) (228)
- Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. (1994) (206)
- The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy (2003) (203)
- Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. (1995) (196)
- Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. (1978) (191)
- A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. (2003) (190)
- Typing of prostate tissue by ultrasonic spectrum analysis (1996) (188)
- Prostate-Specific Membrane Antigen Regulates Angiogenesis by Modulating Integrin Signal Transduction (2006) (178)
- Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. (1989) (175)
- A comparison of the effects of alcohol on mice selectively bred for differences in ethanol sleep-time. (1974) (172)
- Regression of bladder tumors in mice treated with interleukin 2 gene- modified tumor cells [published erratum appears in J Exp Med 1993 Jun 1;177(6):following 1831] (1993) (172)
- Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. (1998) (168)
- Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase (2001) (162)
- Molecular Pathway for Cancer Metastasis to Bone* (2003) (150)
- AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes. (1994) (143)
- Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer. (1977) (142)
- Effect of hypnotics on mice genetically selected for sensitivity to ethanol (1976) (141)
- High energy shock waves suppress tumor growth in vitro and in vivo. (1986) (141)
- Cancer of the prostate: a nutritional disease? (1997) (136)
- Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. (2006) (133)
- Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. (1996) (133)
- CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. (2004) (130)
- Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. (1997) (127)
- Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. (2011) (120)
- Targeted elimination of prostate cancer by genetically directed human T lymphocytes. (2005) (114)
- Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. (2005) (111)
- PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells (2013) (110)
- Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. (2001) (108)
- Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. (1999) (108)
- Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. (1994) (107)
- Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. (1997) (103)
- Comparative analysis of prostate‐specific membrane antigen (PSMA) versus a prostate‐specific membrane antigen‐like gene (2004) (103)
- In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen (2011) (100)
- Free radical production by high energy shock waves--comparison with ionizing irradiation. (1988) (98)
- Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer (2011) (97)
- Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. (2001) (97)
- A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? (2001) (96)
- A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies (2018) (93)
- Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers (2011) (92)
- A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. (2001) (91)
- Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines (2010) (90)
- Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. (1999) (85)
- Histopathologic and ultrastructural correlates of tumor growth suppression by high energy shock waves. (1987) (82)
- Intravesical oncolytic viral therapy using attenuated, replication‐competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model (2001) (81)
- Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. (1995) (80)
- The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. (1997) (80)
- Prostate‐specific suicide gene therapy using the prostate‐specific membrane antigen promoter and enhancer (2000) (76)
- Prostate‐specific membrane antigen (1997) (74)
- Clinical trials of cancer therapies targeting prostate-specific membrane antigen. (2007) (71)
- Mouse orthotopic models for bladder cancer research (2009) (70)
- Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer (2014) (64)
- Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model (2000) (63)
- Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. (1995) (62)
- Prostate-specific Membrane Antigen (PSMA)-specific Monoclonal Antibodies in the Treatment of Prostate and Other Cancers (2004) (61)
- Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. (2000) (60)
- Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. (1999) (60)
- Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin) (2014) (59)
- Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. (2002) (57)
- A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses (2007) (57)
- Targeted treatment of prostate cancer (2007) (57)
- Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination (2005) (56)
- Erratum: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells (Journal of Experimental Medicine (April 1993) 177 (1127)) (1993) (56)
- Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. (2008) (53)
- Heparin‐binding growth factor isolated from human prostatic extracts (1988) (53)
- A re-appraisal of treatment in chronic bacterial prostatitis. (1979) (52)
- The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. (2000) (52)
- Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature (2011) (50)
- Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. (2005) (49)
- In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. (2001) (48)
- Differential effect of alpha-difluoromethylornithine on the in vivo uptake of 14C-labeled polyamines and methylglyoxal bis(guanylhydrazone) by a rat prostate-derived tumor. (1984) (47)
- Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha‐difluoromethylornithine (1982) (46)
- Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. (1991) (46)
- Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. (1982) (45)
- The clinical role of prostate-specific membrane antigen (PSMA). (2002) (45)
- Cytotoxicity of high energy shock waves: methodologic considerations. (1989) (45)
- PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. (2010) (44)
- The regulation of nuclear DNA template restrictions by acidic polymers. (1974) (43)
- Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen (2003) (42)
- Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. (1987) (40)
- Androgen, estrogen and progesterone receptors of the R3327H Copenhagen rat prostatic tumor. (1979) (39)
- Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma. (1989) (36)
- Prostate-specific membrane antigen: present and future applications. (2000) (35)
- Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. (2009) (34)
- Evaluation of Polymeric Nanomedicines Targeted to PSMA: Effect of Ligand on Targeting Efficiency. (2015) (34)
- Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. (2000) (33)
- PURIFICATION AND CHARACTERIZATION OF AN NADH‐LINKED ALDEHYDE REDUCTASE FROM BOVINE BRAIN 1 (1972) (33)
- Improving the biodistribution of PSMA‐targeting tracers with a highly negatively charged linker (2014) (33)
- CD117+ cells in the circulation are predictive of advanced prostate cancer (2014) (33)
- Effects of α-Difluoromethylornithine and Recombinant Interferon-α2 on the Growth of a Human Renal Cell Adenocarcinoma Xenograft in Nude Mice (1984) (32)
- Characterization of a heparin-binding growth factor from adenocarcinoma of the kidney. (1988) (31)
- Suppression of in vitro and in vivo tumor growth by high- energy shock waves (1985) (30)
- Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. (1982) (30)
- Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography (2005) (30)
- Inhibition of mouse bladder tumor proliferation by murine interferon-γ and its synergism with interferon-β (1984) (29)
- Anticarcinoma activity of rhodamine 123 against a murine renal adenocarcinoma. (1988) (29)
- The TMPRSS2–ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition (2015) (29)
- Tumour necrosis factor-induced cytotoxicity is accompanied by intracellular mitogenic signals in ME-180 human cervical carcinoma cells. (1993) (28)
- Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues (2000) (27)
- Mitogenic factors in prostatic tissue and expressed prostatic secretion. (1985) (26)
- Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression (2011) (25)
- An experimental model simulating local recurrence and pelvic lymph node metastasis following orthotopic induction of prostate cancer (1994) (25)
- Differential expression of protein kinase C isozyme messenger RNAs in dunning R-3327 rat prostatic tumors. (1994) (24)
- Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1,2-bis(3,5-dioxopiperazin-1-yl)propane. (1982) (22)
- NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test. (2013) (22)
- Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. (1997) (22)
- Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. (2000) (22)
- TRPM‐2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK‐906 (finasteride), and coumarin (1994) (22)
- Calmodulin antagonist inhibition of polyamine transport in prostatic cancer cells in vitro. (1988) (21)
- Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate-specific membrane antigen. (1995) (20)
- New model for studying the effects of cancer chemotherapeutic agents on the growth of the prostate gland (1975) (20)
- Difluoromethylornithine enhancement of putrescine uptake into the prostate: concise communication. (1982) (19)
- Cytotoxic and non-cytotoxic N-alkyl derivatives of putrescine: effect on polyamine uptake and growth of prostatic cancer cells in vitro. (1987) (19)
- Lack of value of radioimmunoassay for prostatic acid phosphatase as a screening test for prostatic cancer in patients with obstructive prostatic hyperplasia. (1983) (19)
- Cytotoxic activity of a polyamine analogue, monoaziridinylputrescine, against the PC-3 human prostatic carcinoma cell line. (1987) (17)
- Release of chromatin template restriction in rabbit spermatozoa. (1975) (16)
- The effect of High energy shock waves (HESW) on human bone marrow (2004) (16)
- Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: a feasibility study. (2013) (16)
- Transabdominal micro-ultrasound imaging of bladder cancer in a mouse model: a validation study. (2010) (15)
- The in vitro effect of high energy shock waves on human prostate cancer cell line PC-3 (1985) (14)
- Detached Multipinhole Small Animal SPECT Device With Real-Time Calibration (2006) (14)
- Renal cell carcinoma and the clonogenic assay. (1983) (14)
- Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer--focus on prostate-specific membrane antigen? (1999) (14)
- Establishment and characterization of an in vitro clonogenic cell assay for the R-3327-At Copenhagen rat prostatic tumor. (1978) (14)
- Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells. (1995) (12)
- Overview consensus statement. (2001) (12)
- Growth inhibition of a prostate tumor by α-difluoromethylornithine and by cyclophosphamide☆ (1982) (12)
- In vivo targeted contrast enhanced micro-ultrasound to measure intratumor perfusion and vascular endothelial growth factor receptor 2 expression in a mouse orthotopic bladder cancer model. (2011) (11)
- Is combined modality therapy appropriate for apparently localized carcinoma of the prostate? (1991) (10)
- Aminoguanidine reversal of the inhibitory effects of ornithine analogs on the in vitro clonogenic survival of the R3327AT prostate-derived tumor. (1981) (10)
- Selenoprotein P neutralizes lipopolysaccharide and participates in hepatic cell endoplasmic reticulum stress response (2016) (10)
- Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. (2012) (10)
- Growth characteristics and immunogenicity of the R-3327 rat prostate carcinoma. (1978) (9)
- Cytotoxic activity of aziridinyl putrescine enhanced by polyamine depletion with alpha-difluoromethylornithine. (1985) (9)
- Effect of high dose diethylstilbestrol and ICRF-159 on the growth and metastases of the R3327 MAT-LyLu prostate-derived tumor. (1981) (9)
- [Significance of prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase]. (1996) (9)
- alpha-Difluoromethylornithine enhancement of 14C-putrescine uptake by an androgen-dependent prostatic tumor. (1986) (9)
- Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting? (2017) (8)
- High dose estrogen response of the hormone independent R3327-At Copenhagen rat prostatic tumor. (1980) (8)
- 2-5A Ligands—A New Concept for the Treatment of Prostate Cancer (2007) (7)
- Release of DNA template restrictions in rabbit spermatozoa and rat liver nuclei. (1976) (7)
- Prostate specific membrane antigen, a unique glutamate carboxypeptidase: A review of recent findings (1999) (7)
- Effect of surgery and adjuvant chemotherapy on the R3327 MAT‐Ly Lu tumor (1981) (7)
- Future developments of nonhormonal systemic therapy for prostatic carcinoma. (1991) (6)
- Garlic constituents modify expression of biomarkers for human prostatic carcinoma cells (1997) (6)
- Targeted, Activatable, IN VIVO Fluorescence Imaging of Prostate-specific Membrane Antigen (PSMA)-positive Tumors Using the Quenched Humanized J591 Antibody-ICG Conjugate (2011) (6)
- Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors. (1992) (6)
- Identification of a membrane-bound pteroyl poly gamma-glutamyl carboxypeptidase (folate hydrolase) that is highly expressed in human prostatic carcinoma cells (1996) (5)
- Expression of metabotropic glutamate receptors in human prostate cancers and its potential signaling through prostate specific membrane antigen (2004) (5)
- Inhibition of mouse bladder tumor proliferation by murine interferon-gamma and its synergism with interferon-beta. (1984) (5)
- The effect of radiation on prostatic growth. (1976) (5)
- Human renal cell carcinoma xenograft: morphology, growth and chemosensitivities. (1985) (5)
- ANTIBODIES TO THE INTERNAL AND EXTERNAL DOMAINS OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) REACT WITH TUMOR-ASSOCIATED NEOVASCULATURE (1999) (5)
- Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease (2004) (4)
- Understanding Prostate-Specific Membrane Antigen and Its Implication in Prostate Cancer (2005) (4)
- Novel enhanced lung-colonizing variant of murine MBT-2 bladder cancer cells. (2005) (4)
- Structure-Activity Relationships of 2′,5′-Oligoadenylate Analogue Modifications of Prostate-Specific Membrane Antigen (PSMA) Antagonists (2012) (4)
- The relationship of bacterial prostatitis and zinc. (1977) (4)
- Prostatic tumor implantation in the nude mouse via a perineal approach (1997) (3)
- Growth inhibition of a prostate tumor by alpha-difluoromethylornithine and by cyclophosphamide. (1982) (3)
- Effects of alpha-difluoromethylornithine and recombinant interferon-alpha 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice. (1984) (3)
- Specific membrane antigen prostatic hyperplasia. (1993) (3)
- In Vitro Assays for Directing Therapy of Genitourinary Cancers (1984) (2)
- Biology of PSMA As a Diagnostic and Therapeutic Target (2004) (2)
- Immunotherapies for prostate cancer (2005) (2)
- Role of antibody in cytotoxicity by lymphocytes armed against 253J bladder cancer line. (1981) (2)
- Preliminary micro-SPECT and biodistribution study of a novel Tc99m-labeled PSMA tracer derived from RBI1033 (2012) (2)
- Prostate-Specific Membrane Antigen in the Diagnosis of Prostatic Carcinoma (1995) (2)
- CD 117 + cells in the circulation are predictive of advanced prostate cancer (2015) (1)
- New concept in the control of abnormal prostatic growth: combination hormone therapy (1974) (1)
- TARGETED CONTRAST ULTRASOUND DETECTION AND QUANTIFICATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS IN BLADDER CANCER (2009) (1)
- Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin) (2014) (1)
- High dose estrogen response of the hormone-independent R3327-AT and R3327-MAT rat prostatic tumors (1980) (1)
- MICRO-ULTRASOUND IMAGING FOR BLADDER CANCER IN A MURINE MODEL (2008) (1)
- Loss of avidin-binding activity in renal cell carcinoma (1990) (1)
- Establishmentand Characterizationof an in VitroClonogenicCell Assay for the R-3327At CopenhagenRat ProstaticTumor1 (1978) (1)
- 713: Urinary Interleukin-2 or -10 Levels Following Intravesical Liposome-Mediated Interleukin-2 Gene Therapy Plus BCG in Orthotopic Murine Bladder Cancer (2004) (1)
- Effects of intermittent estrogen administration on the R3327H rat prostatic carcinoma (1986) (1)
- Recombinant Antibody Candidates for Treatment of Prostate Cancer (2007) (1)
- PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION POST-NEOADJUVANT ANDROGEN DEPRIVATION THERAPY: COMPARISON OF 7311 AND HYBRITECH PM2J004.5 IN PARAFFIN EMBEDDED PROSTATE TISSUE (1999) (1)
- Commentary RE: Upregulation of PSMA following Androgen Deprivation therapy. (2020) (1)
- Differential gene expression between androgen dependent and independent prostate cancer cell lines (2000) (1)
- Prostate-derived growth factors. (1984) (1)
- Unique prostate cancer marker, prostate specific membrane antigen or PSMA and its role in prostate cancer metastasis. (2004) (0)
- Fluorinated derivatives of N-acetylaspartylglutamate (NAAG) as substrates of prostate specific membrane antigen (PSMA) (2008) (0)
- Synthesis and characterization of RBI-1033, a potent inhibitor of prostate specific membrane antigen that activates RNase L (2005) (0)
- IMMUNOHISTOCHEMICAL COMPARISON OF FIVE ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) IN BENIGN TISSUES (1999) (0)
- Probing the functions of NAAG via NAAG peptidases and MGLUR3 (2008) (0)
- Folate hydrolase assay of tissue extracts from prostate specific membrane antigen (PSMA) transgenic mice (2004) (0)
- In situ gene transfection of bladder cancer cells with retrovirus and herpes simplex virus vector for the treatment of bladder cancer (1997) (0)
- Development of a Biological Basis for PSMA Targeting in Prostate Cancer (2002) (0)
- Transforming 2-5A-PSMA ligand RBI1033 into high affinity PSMA targeting polypeptide ligands for NIR imaging (2011) (0)
- Effect of chemotherapeutic agents on the putrescine transport into R3327MAT-Lu prostate derived tumor cells in vitro (1982) (0)
- 426: Potential Signal Generation Through Metabotropic Glutamate Receptors by Prostate Specific Membrane Antigen (2004) (0)
- Multimodal hyperbranched polymers targeting prostate specific membrane antigen (PSMA) for imaging of prostate cancer (2015) (0)
- AnticarcinomaActivity of Rhodamine123 againsta MurineRenalAdenocarcinoma (1988) (0)
- 695 ROLE OF CIRCULATING NEOPLASTIC PROGENITOR CELLS IN DETECTION AND STAGING OF PROSTATE CANCER (2010) (0)
- New Imaging Strategies for Prostate Cancer (2010) (0)
- Growth Factor Antagonists in Prostatic Cancer: Suramin and Cytotoxic Polyamines as Potential Therapy (1991) (0)
- REVERSAL OF RADIATION RESISTANCE IN LNCaP VIA CERAMIDE SYNTHASE ACTIVATION (1999) (0)
- Cytotoxic putrescine analogue decreases prostatic size (1987) (0)
- Effects of Intermittent Diet hvIstà 1⁄4 bestrol Diphosphate Administration on the R 3327 Rat Prostatic Carcinoma (2006) (0)
- Abstract 983: Effect of optically active Englerin A on global metabolism of A498 renal cell cancer: Impact on carnitine metabolism (2011) (0)
- Mitogenic activity of prostatic extracts. (1987) (0)
- NANOTECHNOLOGY-MEDIATED DELIVERY OF CHEMOTHERAPY IN THE TREATMENT OF UROTHELIAL CARCINOMA (2009) (0)
- Cellular analysis of tumor markers in genitourinary tumors (1997) (0)
- Abstract 4554: Synthesis and Biological Evaluation of New Ligands Targeting Prostate Specific Membrane Antigen (PSMA) (2010) (0)
- A novel [F-18] aluminum-fluoride labeled PSMA tracer with minimal background uptake (2014) (0)
- Molecular weight determination of a growth factor present in human expressed prostatic secretions (1983) (0)
- Preliminary tissue-characterization studies of rat prostate in vivo☆ (1989) (0)
- Targeted multimodal hyperbranched polymers for imaging and therapy of prostate cancer (2016) (0)
- Workshop 5: NAAG and NAALADase: Functional Properties in the Central and Peripheral Nervous System (2008) (0)
- Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific membrane antigen (1995) (0)
- MP61-15 USE OF A NOVEL NEAR-INFRARED IMAGING AGENT FOR INTRA-OPERATIVE PROSTATE CANCER DETECTION (2015) (0)
- Abstract B27: The PARP inhibitor rucaparib radiosensitizes prostate cancer cells, most effectively those that are PTEN-deficient and are expressing ETS gene fusion proteins, which inhibit NHEJ DNA repair (2012) (0)
- Establishment and Characterization of an in Vitro Clonogenic Cell Assay for the R-3327 At Copenhagen Rat Prostatic Tumor 1 (2006) (0)
- Abstract 4057: Negative regulation of prostate specific membrane antigen by androgen is mediated byTMPRSS2-ERGgene fusion in VCaP prostate cancer cells (2010) (0)
- 316 SUCCESSFUL INTRAVESICAL THERAPY FOR BLADDER CANCER UTILIZING PACLITAXEL CONTAINING NANOPARTICLES (2010) (0)
- Abstract C46: DNA damage-induced autophagy is required for efficient DNA repair and cell cycle progression (2012) (0)
- PSMA IS A UNIQUE FOLATE HYDROLASE AND THERAPEUTIC TARGET IN TUMORS. (2002) (0)
- DNA synthesis: a model for studying the effects of cancer chemotherapeutic agents on androgen induced growth of the prostate (1975) (0)
- Bis ( guanylhydrazone ) by a Rat Prostate-derived Tumor C-labeled Polyamines and Methylglyoxal 14 Uptake of in Vivo-Difluoromethylornithine on the α Differential Effect of Updated Version (2006) (0)
- PROSTATE CANCER PATIENT T CELLS GENETICALLY TARGETED TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN SPECIFICALLY AND EFFICIENTLY LYSE PROSTATE CANCER CELLS (1999) (0)
- Expression of Prostate Specific Membrane Antigen in Tumor-Associated Vasculatures of Renal Neoplasms (Poster). (2006) (0)
- Suppression of growth of a human renal cell carcinoma by a combination of interferon and 2-difluoromethylornithine (DFMO) (1984) (0)
- Combination of rucaparib with radiation increases χH2AX and 53BP1 foci leading to persistent DNA damage. (2013) (0)
- Kinetics of androgen repressed gene expression following endocrine ablation and coumarin exposure (1990) (0)
- Characterization of Prostate-Specific Membrane Antigen (PSMA) for Use in Therapeutic and Diagnostic Strategies against Prostate Cancer (2000) (0)
- Molecular pathway for cancer metastasis to bone Short title : prostate cancer – bone matrix interactions (2003) (0)
- The polyamine synthesis inhibitor alpha-difluoromethylornithine (DFMO) enhances putrescine uptake into the androgen stimulated castrated rat prostate (1981) (0)
- Global response to radiation in prostate adenocarcinoma: examination of 12,000 genes and 48,000 ESTs following fractionated versus bolus radiation (2001) (0)
- Inhibition of clonogenicity of PC-3 prostatic cells by monoaziridinyl putrescine with and without pretreatment by the polyamine synthesis inhibitor, difluoromethyl-ornithine (1985) (0)
- A Heparin Binding Growth Factor Isolated from Human Benign Prostatic Hyperplasia and Prostatic Carcinoma (1987) (0)
- Comparison of intravesical interleukin-12 gene therapy and intravesical BCG therapy for murine orthotopic bladder cancer model (2006) (0)
- Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature (2011) (0)
- IN VIVO SUICIDE GENE THERAPY MODEL USING A NEWLY DISCOVERED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) PROMOTER/ENHANCER (2002) (0)
- Prostate specific antigen membranes and its applications (1996) (0)
- Cytokine Gene Modification of Bladder Cancer Cells for the Establishment of Bladder Cancer Vaccine (1996) (0)
- 331 ROBOTIC NEAR INFRARED TARGETED FLUORESCENCE IMAGING IN A MOUSE MODEL OF PROSTATE CANCER (2012) (0)
- 230 INHIBITION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN GENE-EXPRESSION IS MEDIATED BY TMPRSS2:ERG GENE FUSION IN VCAP PROSTATE CANCER CELLS (2010) (0)
This paper list is powered by the following services:
